Probiotic compositions containing clostridiales for inhibiting inflammation
AssigneeEvelo Biosciences, Inc.
InventorsDavid Berry, Johanne Kaplan, Shaila Rahman
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions containing microbial entities are described herein. The pharmaceutical compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the pharmaceutical compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.
Claims32
1-30. (canceled)
A method of treating autoimmune or inflammatory disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a bacterial population of a single bacterial species, wherein the single bacterial species is of the genus Blautia, such that inflammation in the subject is reduced.
A method of treating autoimmune or inflammatory disease in a subject in need thereof, comprising administering to the subject a bacterial population of a single bacterial species, wherein the single bacterial species is selected from the group consisting of Blautia wexlerae, Blautia producta, Blautia obeum, Blautia stercoris and Blautia hydrogenotrophica, such that inflammation in the subject is reduced.
A method of treating autoimmune or inflammatory disease in a subject in need thereof, comprising administering to the subject a bacterial population of a single bacterial species, wherein the single bacterial species is Blautia wexlerae, such that secretion of at least one pro-inflammatory cytokine by immune cells of the subject is reduced, wherein the pro-inflammatory cytokine is selected from the group consisting of IL-1α, IL-6, IFNγ and TNF alpha.
A method of treating autoimmune or inflammatory disease in a subject in need thereof, comprising administering to the subject a bacterial population of a single bacterial species, wherein the single bacterial species is Blautia stercoris, such that secretion of at least one pro-inflammatory cytokine by immune cells of the subject is reduced, wherein the pro-inflammatory cytokine is selected from the group consisting of IL-1α, IL-6, IFNγ and TNF alpha.
A method of treating autoimmune or inflammatory disease in a subject in need thereof, comprising administering to the subject a bacterial population of a single bacterial species, wherein the single bacterial species is Blautia hydrogenotrophica, such that secretion of at least one pro-inflammatory cytokine by immune cells of the subject is reduced, wherein the pro-inflammatory cytokine is selected from the group consisting of IL-1α, IL-6, IFNγ and TNF alpha.
A pharmaceutical composition comprising a bacterial population of a single bacterial species in an amount sufficient to decrease secretion of at least one pro-inflammatory cytokine and/or increase the secretion of at least one anti-inflammatory cytokine in a subject, and a pharmaceutically acceptable excipient, wherein the bacterial species is selected from the group consisting of Blautia wexlerae, Blautia producta, Blautia obeum, Blautia stercoris and Blautia hydrogenotrophica.
Dependencies are inferred from the claim text.